Monthly Archives: November 2017
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia
Use of Yescarta in Acute Lymphoblastic Leukemia
Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute...
Cancer recurrence may be stopped with immunotherapy
October 17, 2017 (Medical News Today)
Scientists and researchers from the UK have set out to investigate why cancer often returns in patients whose...
CAR T-Cell Therapy HCP Guide – Is There A Universal CAR-T Cell Therapy?
Creating a universal CAR T agent could help avoid the lengthy and sometimes dangerous time period from apheresis of T-cells to re-infusion, which on...
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy?
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have...
CAR T-Cell Therapy HCP Guide – Is CAR T-Cell Therapy Approved?
At a July 2017 FDA Oncology Advisory Committee meeting, the panel reviewed Novartis’ CTL019 (tisagenlecleucel), an agent for aggressive pediatric and young adult acute...
